Smart dressings move chronic wound care from intermittent checks to continuous surveillance
Chronic ulcers remain one of the most stubborn failures of routine wound care. Diabetic foot ulcers, pressure ulcers, and venous leg ulcers often worsen quietly, with tissue injury advancing long before a clinician sees an open lesion or necrosis at the bedside. The review published in International Journal of Nanomedicine frames a different model: smart dressings that track physiology continuously, detect pre-ulcer deterioration, and ultimately trigger preventive intervention before skin breakdown becomes visible.
The conceptual shift is important because chronic ulcer prevention has traditionally depended on sporadic inspections, offloading decisions, moisture management, and clinician judgment based on what can be seen at a single visit. Those methods are reactive by design. They are also vulnerable to timing errors, especially when perfusion, inflammation, temperature, pH, or mechanical stress are changing over hours or days rather than during a clinic encounter.
A single wound check cannot capture a destabilizing trajectory.
The review organizes the field around four linked stages: pre-ulcer biological transition, multimodal physiological sensing, AI-assisted data integration and risk prediction, and closed-loop preventive intervention. That framework is clinically useful because it treats ulcer prevention as a dynamic process rather than a static state. A heel or plantar surface can appear intact while microvascular compromise, local heat shifts, pressure concentration, or biochemical changes are already moving the tissue toward failure. Continuous monitoring is intended to detect those changes early enough to matter.
Biological change before skin breaks down
The review places special emphasis on the period before overt ulceration, when tissue is still intact but already under biologic strain. In that phase, the clinical problem is not an open wound alone; it is a trajectory of occult deterioration. Repeated pressure, impaired perfusion, inflammatory activation, and local metabolic change can accumulate silently until the epithelium finally gives way.
That biology explains why conventional surveillance often misses the most actionable window. By the time erythema, drainage, or breakdown is obvious, the window for simple prevention has narrowed. Smart dressings are designed to extend observation into that earlier phase, when reversible changes may still be detectable through temperature variation, moisture dynamics, pH shifts, pressure distribution, or other local signals captured at the skin interface.
Multimodal sensing is replacing single-signal wound checks
The strongest technical theme in the review is not any one sensor, but the convergence of several. Flexible electronics and wearable biointerfaces have enabled dressings that can measure multiple parameters at once, rather than relying on a single readout. In chronic wound care, that matters because ulcer risk is rarely driven by one variable. A patient with diabetes may have neuropathy, altered perfusion, and repetitive mechanical loading operating together; a pressure injury may evolve through sustained compression plus moisture and inflammatory injury; a venous ulcer may reflect hemodynamic compromise layered on skin fragility.
By combining signals, smart dressings aim to reconstruct the physiologic story of the tissue rather than offer a single snapshot. Temporal trends are especially valuable. A rising temperature trend, for example, may be more informative than one isolated reading if it coincides with altered moisture or pH. The review argues that multimodal fusion is central to identifying occult deterioration before a wound opens, because no single biomarker fully captures the path to ulceration.
AI prediction depends on patterns, not isolated measurements
Data from these devices become clinically meaningful only when they are interpreted as patterns. The review gives AI-assisted integration a central role because smart dressings generate dense, time-based signals that require pattern recognition beyond manual review. Machine learning models may eventually help distinguish benign fluctuation from a meaningful pre-ulcer warning, especially when physiology is changing subtly and across several channels at once.
In principle, this is where bioelectronics moves from monitoring to prediction. A dressing that merely stores data is an expensive observer. A dressing that identifies a deteriorating trajectory and flags risk in real time begins to function as a clinical decision-support tool. The review points to temporal trajectories and multimodal fusion as the technical basis for that evolution, but it also makes clear that the field is still early. Most studies remain at the device level, in bench systems or preclinical animals, where signal performance does not yet equal clinical benefit.
Closed-loop prevention is the real destination
The most ambitious vision in the review is not passive surveillance but closed-loop chronic wound management. In that model, sensing is linked to intervention. A smart dressing may eventually prompt a preventive action, adjust therapy, or deliver a local response when risk rises. The review describes this as the transition from reactive monitoring to autonomous or semi-autonomous prevention systems.
That matters because ulcer prevention fails when an abnormal signal is observed but no action follows. Closed-loop design addresses that gap directly. If a dressing detects rising pressure risk, biochemical deterioration, or local instability, the system can theoretically trigger a response before tissue injury becomes irreversible. The review also notes emerging interest in self-powered systems, edge AI, and autonomous therapeutic platforms, all of which would reduce reliance on external power sources or constant data transmission.
A dressing that senses without acting may document failure too late.
The translational gap remains wide
The review is unusually direct about the distance between promise and proof. Most supporting evidence still comes from benchtop experiments, device engineering studies, or short-term feasibility work in animals. Prospective clinical validation showing measurable reductions in ulcer incidence remains largely absent. That is the central limitation, and it governs how these technologies should be interpreted today.
The gap is not trivial. Ulcer incidence is the endpoint that matters most for patients, caregivers, and health systems. A sensor can perform well in a lab and still fail to prevent a pressure injury at the bedside if it is uncomfortable, fragile, inaccurate during real-world wear, or disconnected from a practical response pathway. The review therefore treats translational validation as the next major hurdle, not a minor implementation detail.
Three prevention settings will shape future trials
The review separates ulcer prevention into three clinical scenarios: primary prevention on intact high-risk skin, prevention of recurrence on healed skin, and prevention of deterioration in existing wounds. That distinction is clinically useful because each scenario poses a different biological and operational problem. Intact skin requires early risk detection. Healed skin requires surveillance for recurrence. An existing wound needs monitoring for further breakdown, infection, or stalled repair.
Each setting will likely need a different sensor mix, alert threshold, and intervention pathway. A system built to protect a neuropathic diabetic foot may not be optimized for sacral pressure injury prevention or venous ulcer recurrence. Future studies will need to define which biomarkers best predict each form of failure, how much lead time is clinically meaningful, and whether automated responses improve outcomes beyond usual care.
For now, the field stands at an engineering-rich but clinically underproven stage. The technology is moving quickly; the question is whether it can demonstrate fewer ulcers, not just richer data.